US Pharma MarketingDaiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Enhertu’s market conquest is continuing apace. Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But while arriving nearly two months early, the adjuvant label comes with a catch.
Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But while arriving nearly two months early, the adjuvant label comes with a catch.
Source: FiercePharma